



Overview of Oral Antiseptics And Their Potential Benefits for Treating HIV-1 and HSV-1

Falkler Queline*

Department of Public Health and Biomedical Innovation, Queensland University of Technology, Queensland, Australia

DESCRIPTION

The Human Immunodeficiency Virus-1 (HIV-1) is one of the most widely known viruses in the world today. It is a deadly infection that slowly breaks down the body's immune system, making it vulnerable to a variety of illnesses and diseases. Additionally, Herpes Simplex Virus Type 1 (HSV-1), also known as oral herpes, is a virus that affects the facial area of an individual by causing painful blisters on the skin. Both HIV-1 and HSV-1 are incurable infections, but there are treatments that can help manage symptoms. One such treatment is the use of oral antiseptics [1].

Oral antiseptics are products that contain ingredients such as hydrogen peroxide, or other sterilizing agents. These products work by killing bacteria or preventing their growth on surfaces or objects. When used orally, they can help control or reduce oral plaque buildup caused by HIV-1 and HSV-1 infections. As plaque accumulates more rapidly in individuals with weakened immune systems, due to an HIV-1 or HSV-1 infection, it can cause serious dental problems if not treated properly [2].

Using oral antiseptics twice daily has been shown to help reduce plaque buildup caused by HIV-1 and HSV-1 infections. A study conducted in 2015 found that using an oral antiseptic containing hydrogen peroxide for 20 minutes every day was able to reduce plaque levels significantly after two weeks of regular use. This kind of product also helps reduce inflammation associated with HIV-1 and HSV-1 infections in the mouth. Oral antiseptics are safe to use and can be found over the counter at your local pharmacy or grocery store. However, when choosing an oral antiseptic it's important to read all directions before using it as some products may contain ingredients which could irritate the gums or cause unwanted side effects [3].

Oral antiseptics, which are agents that are used to disinfect the mouth and kill bacteria, have been found to be effective in treating HIV-1 (Human Immunodeficiency Virus 1) and HSV-1 (Herpes Simplex Virus 1). HIV-1 is a retrovirus that can cause immunodeficiency, while HSV-1 is a herpes virus that is known

to cause cold sores. The use of oral antiseptics offers several potential benefits for patients suffering from these two viruses [4].

The first benefit of using oral antiseptics for HIV-1 and HSV-1 is the reduction in transmission risks. Oral antiseptics kill bacteria on contact, which can lower the risk of transmitting these viruses through saliva or other bodily fluids. In addition to this, it has been found that some oral antiseptics are also effective in reducing the amount of virus present in saliva, which further reduces transmission risk [5].

Benefits of using oral antiseptics to treat HIV-1 and HSV-1, including antiviral activity, improved immune response, and reduced risk of secondary infections antiviral agents like oral antiseptics have long been used to effectively treat immunodeficiency virus-1 (HIV-1) and Herpes Simplex Virus-1 (HSV-1). By inhibiting or completely preventing the growth and spread of these viruses, they can reduce the severity of symptoms in those with HIV-1 or HSV-1. In addition to their antiviral activity, oral antiseptics also provide numerous other benefits for those suffering from these viral infections. One major benefit is an improved immune response to the viruses. Oral antiseptics can stimulate certain receptors in the body that produce a stronger immune response, allowing it to better combat the viruses. This ultimately leads to a decrease in symptoms associated with both HIV-1 and HSV-1. Furthermore, an improved immune response means that individuals are less susceptible to secondary infections brought on by weakened immunity. Another benefit of using oral antiseptics is their ability to reduce the risk of transmission between individuals with HIV-1 or HSV-1. Studies have shown that when used properly, oral antiseptics can effectively reduce transmission rates by preventing viral transfer and reducing replication in cells. This makes them a powerful tool for minimizing the spread of these diseases within communities [6].

Immunodeficiency Virus-1 (HIV-1) is a virus that weakens the body's immune system, making it difficult to fight off infections. As such, there is risk of increased susceptibility to bacterial and

Correspondence to: Falkler Queline, Department of Public Health and Biomedical Innovation, Queensland University of Technology, Queensland, Australia, E-mail: quelineluc.falklerk@email.com

Received: 01-Dec-2023, Manuscript no: JTD-23-24373, **Editorial assigned:** 05-Dec-2023, PreQC no: JTD-23-24373 (PQ), **Reviewed:** 19-Dec-2023, QC no: JTD-23-24373, **Revised:** 27-Dec-2023, Manuscript no: JTD-23-24373 (R), **Published:** 04-Jan-2024, DOI: 10.35241/2329-891X.24.11.419

Citation: Queline F (2024) Overview of Oral Antiseptics And Their Potential Benefits for Treating HIV-1 and HSV-1. *J Trop Dis*. 14:419

Copyright: © 2024 Queline F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

fungal infections when oral antiseptics are used to treat HIV-1 and HSV-1, an incorrect dosage or extended period of use of these agents can cause irritation to the mouth lining and throat including ulcerations which can be painful and uncomfortable for patients [7]. Furthermore, overuse of oral antiseptics can lead to an imbalance in the natural flora of the mouth, leading to an overgrowth of bacteria which may produce toxins that could further harm the patient [8]. When used under medical supervision and in accordance with directions, however, these potential risks can be mitigated. It is important that individuals take proper precautions when using oral antiseptics to treat HIV-1 and HSV-1 by adhering to any instructions provided by their doctor or pharmacist regarding dosage and duration of treatment as well as usage instructions [9]. Individuals should also be aware of possible side effects including allergies or other adverse reactions as well as any contraindications they may have depending on underlying health conditions or medications they are taking simultaneously [10].

REFERENCES

1. Adithya M. Liver Transplantation during the COVID-19 Pandemic: Viruses, Vaccines and Beyond. *J Clin Exp Hepatol.* 2021;11(5): 411-413.
2. Sett S. Access and benefit-sharing by the European Virus Archive in response to COVID-19. *The Lancet Microbe.* 2021;3(4):316-323.
3. Grimwood K. Interference between rhinovirus and other RNA respiratory viruses in the first 2-years of life: A longitudinal community-based birth cohort study. *J Clin Virol.* 2022;155(5): 105-107.
4. Cassimatis IR. Housing instability is associated with failure to achieve virologic control among pregnant individuals with HIV. *J Obstet Gynecol.* 2021;3(5):107-112.
5. Beale S. Workplace contact patterns in England during the COVID-19 pandemic: Analysis of the Virus Watch prospective cohort study. *The Lancet Regional Health-Europe.* 2022;16(5):352-361.
6. Fadda M. Decision-making on COVID-19 vaccination: A qualitative study among health care and social workers caring for vulnerable individuals. *SSM-Qualitative Research in Health.* 2022;2(3): 100-108.
7. Quan Wang. Fabrication of an allyl- β -cyclodextrin based monolithic column with triallyl isocyanurate as co-crosslinker and its application in separation of lipopeptide antibiotics by HPLC. *Microchem. J.* 2021;168:319-328.
8. Lei Ni. Development and validation of a novel approach based on ultrasonic-assisted enzymatic extraction and RP-UHPLC for simultaneous determination of astaxanthin isomers and alpha-tocopherol in *Haematococcus pluvialis* derived supplements. *J. Pharm. Biomed.* 2021;193:241-254.
9. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoromycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. *Clin Infect Dis.* 2012;5:8-15.
10. Kimura M, Yaguchi T, Sutton DA, Fothergill AW, Thompson EH, Wickes BL. Disseminated human conidiobolomycosis due to *Conidiobolus lampraegus*. *J Clin Microbiol.* 2011;49(2):752-756.